To date, four vaccines have been authorised for emergency use and under conditional approval by the European Medicines Agency to prevent COVID-19: Comirnaty, COVID-19 Vaccine Janssen, Spikevax (previously COVID-19 Vaccine Moderna) and Vaxzevria (previously COVID-19 Vaccine AstraZeneca). Although the benefit–risk profile of these vaccines was proven to be largely favourable in the general population, evidence in special cohorts initially excluded from the pivotal trials, such as pregnant and breastfeeding women, children/adolescents, immunocompromised people and persons with a history of allergy or previous SARS-CoV-2 infection, is still limited. In this narrative review, we critically overview pre- and post-marketing evidence on the potential benefits and risks of marketed COVID-19 vaccines in the above-mentioned special cohorts. In addition, we summarise the recommendations of the scientific societies and regulatory agencies about COVID-19 primary prevention in the same vaccinee categories.

COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety / Luxi N.; Giovanazzi A.; Capuano A.; Crisafulli S.; Cutroneo P.M.; Fantini M.P.; Ferrajolo C.; Moretti U.; Poluzzi E.; Raschi E.; Ravaldi C.; Reno C.; Tuccori M.; Vannacci A.; Zanoni G.; Trifiro G.; Trifiro G.; Petrelli G.; Girotti S.; Arzenton E.; Magro L.; Lora R.; Bellantuono D.; Sabaini A.; Firenze A.; Zodda D.; Guidotti F.; Zappone M.; Alagna B.; Spina E.; Minore C.; Costantino C.; Conforto A.; Vitale F.; Morreale I.; Marsala L.; Farinella D.; Bavetta S.; Sapigni E.; Potenza A.M.; Podetti D.; Nikitina V.; Ricciardelli R.; Mogheiseh N.; Croce S.; Paltrinieri B.; Castellani S.; Sangiorgi E.; Selleri M.; Lucchesi S.; Catucci G.; Savini D.; Sacripanti C.; Faccioli M.; Romio M.S.; Rossi L.; Radici S.; Negri G.; Fares L.; Ajolfi C.; Fadda A.; Chiarello A.; Pieraccini F.; Pappalardo F.; Bonaiuti R.; Lombardi N.; Crescioli G.; Tessari R.; Zandona E.; Marchiori F.; Chiamulera C.; Senna G.; Crivellaro M.A.; Cancian M.; Venturini F.; Ferri M.; Leonardi L.; Orzetti S.; Caccin E.; Baldo P.; Rafaniello C.; Pagliaro C.; Mercaldo M.; Fucile A.; di Giorgio A.; Tari M.; Manna S.; Farina G.; Di Mauro C.; De Carlo I.; Senesi I.; Pileggi C.; Palleria C.; Gallelli L.; De Sarro G.; Trabace L.; Morgese M.; Schiavone S.; Tucci P.; Bove M.; Lapi F.; Cricelli C.; Racagni G.; Tonolo S.; Leopardi E.; Fava G.; Giuffrida S.; Amato V.; Gambera M.; Montresor V.. - In: DRUG SAFETY. - ISSN 0114-5916. - ELETTRONICO. - 44:(2021), pp. 1247-1269. [10.1007/s40264-021-01131-6]

COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety

Capuano A.;Crisafulli S.;Ravaldi C.;Vannacci A.;Vitale F.;Radici S.;Negri G.;Fadda A.;Bonaiuti R.;Lombardi N.;Crescioli G.;Pagliaro C.;Manna S.;Farina G.;Di Mauro C.;Tucci P.;
2021

Abstract

To date, four vaccines have been authorised for emergency use and under conditional approval by the European Medicines Agency to prevent COVID-19: Comirnaty, COVID-19 Vaccine Janssen, Spikevax (previously COVID-19 Vaccine Moderna) and Vaxzevria (previously COVID-19 Vaccine AstraZeneca). Although the benefit–risk profile of these vaccines was proven to be largely favourable in the general population, evidence in special cohorts initially excluded from the pivotal trials, such as pregnant and breastfeeding women, children/adolescents, immunocompromised people and persons with a history of allergy or previous SARS-CoV-2 infection, is still limited. In this narrative review, we critically overview pre- and post-marketing evidence on the potential benefits and risks of marketed COVID-19 vaccines in the above-mentioned special cohorts. In addition, we summarise the recommendations of the scientific societies and regulatory agencies about COVID-19 primary prevention in the same vaccinee categories.
2021
44
1247
1269
Goal 3: Good health and well-being
Luxi N.; Giovanazzi A.; Capuano A.; Crisafulli S.; Cutroneo P.M.; Fantini M.P.; Ferrajolo C.; Moretti U.; Poluzzi E.; Raschi E.; Ravaldi C.; Reno C.; ...espandi
File in questo prodotto:
File Dimensione Formato  
57 Luxi et al, 2021.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 927.32 kB
Formato Adobe PDF
927.32 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1266678
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 95
  • ???jsp.display-item.citation.isi??? 92
social impact